Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 15
1994 35
1995 24
1996 29
1997 22
1998 17
1999 19
2000 14
2001 15
2002 17
2003 11
2004 23
2005 7
2006 10
2007 5
2008 3
2009 9
2010 11
2011 10
2012 10
2013 7
2014 7
2015 6
2016 1
2017 12
2018 13
2019 18
2020 14
2021 10
2022 25
2023 18
2024 8
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

424 results

Results by year

Filters applied: . Clear all
Page 1
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group. Giovannoni G, et al. N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089960 Free article. Clinical Trial.
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.
Roos I, Sharmin S, Malpas C, Ozakbas S, Lechner-Scott J, Hodgkinson S, Alroughani R, Eichau Madueño S, Boz C, van der Walt A, Butzkueven H, Buzzard K, Skibina O, Foschi M, Grand'Maison F, John N, Grammond P, Terzi M, Prévost J, Barnett M, Laureys G, Van Hijfte L, Luis Sanchez-Menoyo J, Blanco Y, Oh J, McCombe P, Ramo Tello C, Soysal A, Prat A, Duquette P, Yamout BI, Khoury S, van Pesch V, Macdonell R, José Sá M, Slee M, Kuhle J, Maimone D, Spitaleri D, Willekens B, Asmi AA, Tallantyre E, Robertson NP, Coles A, L Brown JW, Kalincik T. Roos I, et al. Mult Scler. 2024 Aug;30(9):1163-1175. doi: 10.1177/13524585241267211. Epub 2024 Aug 1. Mult Scler. 2024. PMID: 39087208
Cladribine (Mavenclad) for multiple sclerosis.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2019 Jul 29;61(1577):118-120. Med Lett Drugs Ther. 2019. PMID: 31381552 Review. No abstract available.
Cladribine: mechanisms and mysteries in multiple sclerosis.
Jacobs BM, Ammoscato F, Giovannoni G, Baker D, Schmierer K. Jacobs BM, et al. J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1266-1271. doi: 10.1136/jnnp-2017-317411. Epub 2018 Jul 10. J Neurol Neurosurg Psychiatry. 2018. PMID: 29991490 Review.
Cladribine in indolent non-Hodgkin's lymphoma.
Sigal DS, Saven A. Sigal DS, et al. Expert Rev Anticancer Ther. 2008 Apr;8(4):535-45. doi: 10.1586/14737140.8.4.535. Expert Rev Anticancer Ther. 2008. PMID: 18402520 Review.
424 results